TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2024

Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects.

Wei Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.